These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 27965277)
1. Treatment of metastatic pancreatic neuroendocrine tumors: relevance of ENETS 2016 guidelines. Foulfoin M; Graillot E; Adham M; Rousset P; Forestier J; Hervieu V; Robinson P; Scoazec JY; Lombard-Bohas C; Walter T Endocr Relat Cancer; 2017 Feb; 24(2):71-81. PubMed ID: 27965277 [TBL] [Abstract][Full Text] [Related]
2. Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumours Resistant to Prior Treatments. Angelousi A; Kamp K; Kaltsatou M; O'Toole D; Kaltsas G; de Herder W Neuroendocrinology; 2017; 105(4):394-402. PubMed ID: 28122378 [TBL] [Abstract][Full Text] [Related]
3. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms. Mizuno Y; Kudo A; Akashi T; Akahoshi K; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Tanaka S; Tateishi U; Tanabe M J Cancer Res Clin Oncol; 2018 Jun; 144(6):1155-1163. PubMed ID: 29602973 [TBL] [Abstract][Full Text] [Related]
4. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Strosberg JR; Cheema A; Weber JM; Ghayouri M; Han G; Hodul PJ; Kvols LK Ann Surg; 2012 Aug; 256(2):321-5. PubMed ID: 22415420 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor. Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928 [TBL] [Abstract][Full Text] [Related]
6. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. Pusceddu S; Vernieri C; Di Maio M; Marconcini R; Spada F; Massironi S; Ibrahim T; Brizzi MP; Campana D; Faggiano A; Giuffrida D; Rinzivillo M; Cingarlini S; Aroldi F; Antonuzzo L; Berardi R; Catena L; De Divitiis C; Ermacora P; Perfetti V; Fontana A; Razzore P; Carnaghi C; Davì MV; Cauchi C; Duro M; Ricci S; Fazio N; Cavalcoli F; Bongiovanni A; La Salvia A; Brighi N; Colao A; Puliafito I; Panzuto F; Ortolani S; Zaniboni A; Di Costanzo F; Torniai M; Bajetta E; Tafuto S; Garattini SK; Femia D; Prinzi N; Concas L; Lo Russo G; Milione M; Giacomelli L; Buzzoni R; Delle Fave G; Mazzaferro V; de Braud F Gastroenterology; 2018 Aug; 155(2):479-489.e7. PubMed ID: 29655834 [TBL] [Abstract][Full Text] [Related]
7. Treatment Patterns and Burden of Illness in Patients Initiating Targeted Therapy or Chemotherapy for Pancreatic Neuroendocrine Tumors. Broder MS; Chang E; Reddy SR; Neary MP Pancreas; 2017 Aug; 46(7):891-897. PubMed ID: 28697129 [TBL] [Abstract][Full Text] [Related]
8. Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study. Yao JC; Pavel M; Lombard-Bohas C; Van Cutsem E; Voi M; Brandt U; He W; Chen D; Capdevila J; de Vries EGE; Tomassetti P; Hobday T; Pommier R; Öberg K J Clin Oncol; 2016 Nov; 34(32):3906-3913. PubMed ID: 27621394 [TBL] [Abstract][Full Text] [Related]
9. Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute. Shin Y; Ha SY; Hyeon J; Lee B; Lee J; Jang KT; Kim KM; Park YS; Park CK Cancer Res Treat; 2015 Oct; 47(4):738-46. PubMed ID: 25687852 [TBL] [Abstract][Full Text] [Related]
10. Everolimus in Pancreatic Neuroendocrine Carcinomas G3. Panzuto F; Rinzivillo M; Spada F; Antonuzzo L; Ibrahim T; Campana D; Fazio N; Delle Fave G Pancreas; 2017 Mar; 46(3):302-305. PubMed ID: 28099254 [TBL] [Abstract][Full Text] [Related]
11. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial. Lombard-Bohas C; Yao JC; Hobday T; Van Cutsem E; Wolin EM; Panneerselvam A; Stergiopoulos S; Shah MH; Capdevila J; Pommier R Pancreas; 2015 Mar; 44(2):181-9. PubMed ID: 25479584 [TBL] [Abstract][Full Text] [Related]
12. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial. Neychev V; Steinberg SM; Cottle-Delisle C; Merkel R; Nilubol N; Yao J; Meltzer P; Pacak K; Marx S; Kebebew E BMJ Open; 2015 May; 5(5):e008248. PubMed ID: 25991462 [TBL] [Abstract][Full Text] [Related]
13. Clinical course of neuroendocrine tumors with different origins (the pancreas, gastrointestinal tract, and lung). Kim SJ; Kim JW; Oh DY; Han SW; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ Am J Clin Oncol; 2012 Dec; 35(6):549-56. PubMed ID: 21659833 [TBL] [Abstract][Full Text] [Related]
14. Multidisciplinary treatment strategy for advanced pancreatic neuroendocrine tumors- a single center experience. Tsuchikawa T; Hirano S; Tanaka E; Kato K; Matsumoto J; Sichinohe T Hepatogastroenterology; 2012; 59(120):2623-6. PubMed ID: 22497945 [TBL] [Abstract][Full Text] [Related]
15. Recent Updates in the Management of Advanced Pancreatic Neuroendocrine Tumors. Cho CM Korean J Gastroenterol; 2019 Mar; 73(3):124-131. PubMed ID: 31013555 [TBL] [Abstract][Full Text] [Related]
17. A retrospective cohort study of pancreatic neuroendocrine tumors at single institution over 15 years: New proposal for low- and high-grade groups, validation of a nomogram for prognosis, and novel follow-up strategy for liver metastases. Ye L; Ye H; Zhou Q; Li Z; Lin Q; Tan L; Gao W; Fu Z; Zheng S; Chen R Int J Surg; 2016 May; 29():108-17. PubMed ID: 27000717 [TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea. Lee KJ; Cho JH; Lee SH; Song SY; Lee KH; Jeong S; Ryu JK; Woo SM; Bang S; Lee JK; Lee TH; Paik WH; Kim YT; Lee WJ Cancer Chemother Pharmacol; 2017 Oct; 80(4):799-805. PubMed ID: 28884280 [TBL] [Abstract][Full Text] [Related]
19. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237 [TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China. Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]